Cordis tells US to prepare for paradigm shift in CAD (coronary artery disease) treatment
This article was originally published in Clinica
Executive Summary
If Johnson & Johnson's sales projections are to be believed, up to 75% of US cardiologists will use Cordis' Cypher sirolimus-eluting stent once it gains US approval, which is said to be imminent.